PositiveID Corporation (fka PSID)

[greaseyfingers]

Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract

August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.

PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.

In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.

The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.

The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.

The request for proposal got postponed by DHS, as we all know, into 2013.

As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.

More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .

"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.

"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."

Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.

The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.

PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.

http://www.investorideas.com/news/2012/main/08062.asp